MIDATECH PHARMA PLC-ADR (MTP)

Company Profile

Midatech Pharma Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 20 full-time employees. The company went IPO on 2014-12-08. The firm is focused on improving the bio-delivery and biodistribution of medicines. The firm's technologies include Q-Sphera, MidaSolve and MidaCore. Q-Sphera technology focusses on long acting injectables using three-dimensional (3D) printing technology. MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility at biological potential of Hydrogen (pH) extending available routes of administration, including direct-to-tumor delivery. The company has a pipeline of approximately 10 earlier stage programmes, which includes MTD211 (Schizophrenia, MDD), MTD219 (Prophylaxis, transplant rejection), MTX223, MTX213, MTX214, MTX110 (Glioblastoma), MTX110 (Brain Cancer in Children (DIPG)), MTX110 (Medulloblastoma) and MTX114 (Psoriasis).

Company Info

MIDATECH PHARMA PLC-ADR

Oddfellows Hse, 19 Newport Road

Abingdon OXFORDSHIRE CF24 0AA

P: 4401235888300.0

CEO: Stephen Stamp

Employees: 20

Website: http://www.midatechpharma.com/